Company intelligence / Profile preview

Ningbo Xijian Pharmaceutical Technology Co., Ltd.

Ningbo/Cixi City, Zhejiang Province, China

Ownership: Private
Development stage: Other

Overview

Ningbo Xijian Pharmaceutical Technology is developing EG017, a selective androgen receptor modulator intended to treat stress urinary incontinence and other conditions related to androgen deficiency in middle-aged and elderly populations. The company has conducted multiple clinical trials, including a multicenter, randomized, double-blind Phase IIb study for stress urinary incontinence. Some of these studies have been terminated or completed as of early 2025. No approved products are reported.

Therapeutic areas: OphthalmologyWomen's Health
Modalities: Small molecules (specifically selective androgen receptor modulators, SARMs)
Industry: Biotech

Partnerships

Beijing New Leading Zhengzhou Deep Blue Sea Biomedicine/Deep Blue Sea CRO supported the clinical trial operations for EG017.

Beyond the preview

Go deeper on Ningbo Xijian Pharmaceutical Technology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ningbo Xijian Pharmaceutical Technology Co., Ltd..